Hemab Therapeutics Holdings, Inc.
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$22.7M
- Total assets
- $175.3M
- Market cap
- $1.2B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.2B
- Shares outstanding
- 46.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 1, 2026
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $22.7M.
- Trading 25% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Hemab Therapeutics Holdings, Inc..
Write a review
News about Hemab Therapeutics Holdings, Inc.
News & sentiment via Polygon.io
